Latest by Polly Clayden
Three posters at CROI 2015 described pharmacokinetics of antiretrovirals in pregnancy for rilpivirine, etravirine and raltegravir. None of the studies suggested that dose adjustment is required.
Three posters at CROI 2015 showed new pediatric elvitegravir data. The posters described preliminary safety in the 6-to-12-year-old age group, and safety, efficacy, pharmacokinetics and resistance in 12-to-18 year olds receiving elvitegravir in fixed...
Preliminary data using linkage between three U.K. HIV surveillance databases showed genetic diversity among HIV-positive pregnant women in England and Wales. The women had low prevalence of transmitted antiretroviral drug resistance -- consistent wit...
Unintended Pregnancies With Levonorgestrel Implant Due to Drug Interactions With Efavirenz-Based Antiretroviral Therapy
Three unintended pregnancies in women with levonorgestrel sub-dermal implants, receiving efavirenz-based antiretroviral therapy in a pharmacokinetic study, were reported in a late breaker presentation at CROI 2015.
3-Drug Antiretroviral Therapy Best for Preventing Vertical Transmission to Infants: Results From the PROMISE Study
Taking a three-drug antiretroviral therapy combination in pregnancy was more effective in preventing mother-to-child transmission than taking one drug during pregnancy, another in labor and two after delivery.
3 in 5 Breastfeeding Women With High HIV Viral Loads Are Undiagnosed in Kenya, Malawi and South Africa
A large proportion of pregnant and breastfeeding women with high viral load were undiagnosed in a study conducted in Kenya, Malawi and South Africa. David Mamen from Médecins sans Frontières presented these findings at CROI 2015.
Lopinavir/Ritonavir Superior to Nevirapine in Children Over 3 Years Old: IMPAACT P1060 Study Results
Long-term virologic suppression was superior in children receiving lopinavir/ritonavir-based antiretroviral therapy compared with nevirapine-based regimens at five-year follow up in the IMPAACT P1060 trial.
Point of Care HIV PCR Test for Infant Diagnosis: Good Performance but Poorer Results in Youngest Age Group
A point of care (POC) assay performed well in infant diagnosis in a large laboratory study. But its error rate of 6% has implications for implementation and its newborn performance requires further evaluation.
Tenofovir was well tolerated in children for up to 336 weeks, according to preliminary efficacy and safety data presented at CROI 2015.
Although 400 mg efavirenz (EFV) is gives cerebrospinal fluid exposure (CSF) exposure of EFV above that required for HIV suppression, exposure of metabolites might still be within the concentration range associated with toxicities -- according to find...